Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Product Surveillance, Postmarketing | 2 | 2013 | 37 | 0.900 |
Why?
|
| Medical Records | 2 | 2013 | 119 | 0.850 |
Why?
|
| Rotavirus Vaccines | 2 | 2013 | 8 | 0.560 |
Why?
|
| Consumer Product Safety | 1 | 2013 | 11 | 0.450 |
Why?
|
| Uncertainty | 1 | 2013 | 71 | 0.430 |
Why?
|
| Patient Safety | 1 | 2013 | 212 | 0.370 |
Why?
|
| Models, Statistical | 1 | 2013 | 574 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 865 | 0.330 |
Why?
|
| Vaccines, Attenuated | 2 | 2013 | 51 | 0.230 |
Why?
|
| Acute Kidney Injury | 2 | 2015 | 295 | 0.190 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 200 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 1052 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 394 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 164 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 63 | 0.120 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 39 | 0.120 |
Why?
|
| Food Contamination | 1 | 2013 | 31 | 0.120 |
Why?
|
| Mass Screening | 1 | 2018 | 618 | 0.120 |
Why?
|
| Cisplatin | 1 | 2016 | 612 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 231 | 0.120 |
Why?
|
| Oryza | 1 | 2013 | 40 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 329 | 0.110 |
Why?
|
| Intussusception | 1 | 2013 | 16 | 0.110 |
Why?
|
| Normal Distribution | 1 | 2013 | 37 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 236 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 301 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 158 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 373 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2013 | 296 | 0.100 |
Why?
|
| Arsenic | 1 | 2013 | 251 | 0.100 |
Why?
|
| Carcinoma | 1 | 2013 | 436 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 408 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2357 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 878 | 0.070 |
Why?
|
| Graft vs Host Reaction | 1 | 2006 | 15 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 1076 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3362 | 0.070 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2006 | 86 | 0.070 |
Why?
|
| Infant | 1 | 2013 | 3046 | 0.070 |
Why?
|
| RNA Editing | 1 | 2006 | 34 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2006 | 267 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2903 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2360 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 123 | 0.060 |
Why?
|
| Middle Aged | 7 | 2018 | 25028 | 0.060 |
Why?
|
| Humans | 9 | 2018 | 86643 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 1939 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1204 | 0.050 |
Why?
|
| Adult | 5 | 2018 | 25648 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 7993 | 0.040 |
Why?
|
| Female | 6 | 2018 | 44532 | 0.040 |
Why?
|
| Aged | 4 | 2016 | 18415 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 2767 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 41 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 463 | 0.030 |
Why?
|
| Male | 5 | 2016 | 40965 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1163 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 338 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 318 | 0.030 |
Why?
|
| Dermatitis | 1 | 2013 | 32 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 334 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 176 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 155 | 0.030 |
Why?
|
| Risk Factors | 2 | 2014 | 5417 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 229 | 0.030 |
Why?
|
| Drinking Water | 1 | 2013 | 64 | 0.030 |
Why?
|
| Bangladesh | 1 | 2013 | 318 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1538 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2013 | 166 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 996 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 678 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 486 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2013 | 328 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 860 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 999 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 8489 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 329 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1019 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4213 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2271 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1239 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1577 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1379 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1801 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 3968 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1313 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3640 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3679 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6509 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 5210 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2006 | 971 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1540 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 5976 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 8981 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 3092 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 11352 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 26582 | 0.000 |
Why?
|